Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C1140680 (ovarian cancer)
 28,141 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To minimize immunological interferences on the subrenal capsule (SRC) assay, a new immunosuppressor, mizoribin (MZB: Bredinin) alone or combined with cyclosporin A (ScA) was evaluated by an experimental SRC assay system using a rat ovarian cancer tissue. Daily applications of MZB (200 mg/kg) for 7 days following the xenograft of cancer tissue were insufficient to suppress immunological reactions of the recipient mice, and all the grafted cancer tissues were rejected. Although CsA monotreatment (60 mg/kg of CsA given daily for 7 days) successfully suppressed the host immune reaction, enhanced toxicities of CsA in combination with anticancer agents caused high lethal rate of host mice during the experimental chemotherapy. Sequential use of CsA on day 0 to day 2 followed by MZB on day 3, 5 and 7 brought the most favorable results with minimal host reactions and toxicities. An anticancer screening test using the modified SRCA accurately reflected the results of experimental chemotherapy against the rat ovarian cancer. The immunosuppressive treatment which minimizes immunological interferences with SRC assay chemoscreening test.
 ...
PMID:A sequential immunosuppressive treatment with mizoribin (Bredinin) plus cyclosporin A on the subrenal capsule assay. 177 8